Biography
Bruno C. Medeiros, MD is associate professor of medicine. Dr. Medeiros graduated from the Universidade Federal do Parana with a medical degree, in 1998. He completed his post-graduate training at the University of Colorado in Denver and the Princess Margaret Hospital in Toronto (Acute leukemia fellowship). Dr. Medeiros’ clinical interests include management of advanced hematologic malignancies, including AML, ALL, MDS and CML. His clinical research interest focuses on the development of novel therapeutic regimens for patients with acute leukemia, with special interest in the development of novel therapeutic strategies for patients with acute myeloid leukemia. He is the leader in several institutional investigator initiated clinical trials, active investigator in collaborative multi-institutional clinical studies and an active member of the SWOG acute leukemia panel. Dr. Medeiros has authored more than 120 peer-reviewed manuscripts. Dr. Medeiros has served as the track leader for ASCO meeting Leukemia, Myelodysplasia and Transplantation scientific review subcommittee, he functions as the Associate Editor of the Leukemia Panel for Cancer.Net, he is a member of the editorial board for Leukemia Research and serves as a reviewer for several specialized journals, such as Blood, Leukemia, Haematologica and Cancer, among others. Previously, he served as the director of the inpatient hematology service and also director of Cancer Center ITA services at Stanford Comprehensive Cancer Center.
View Full Biography »
Professional Summary
Education & Certifications
- Fellowship: University of Colorado Denver Hematology and Oncology Fellowship (2005) CO
- Fellowship, Acute leukemia, Princess Margaret Hospital - University of Toronto (2006)
- Board Certification: American Board of Internal Medicine, Hematology (2006)
- Residency: University of Colorado Health Science Center (2002) CO
- Internship: University of Connecticut Health Center (2000) CT
- Medical Education: University Federal Do Parana (1998) Brazil
Administrative Appointments
- Acute Leukemia Panel Member, Southwest Oncology Group (SWOG) (2007 - 2016)
- Director, Stanford Hospital Hematology Inpatient service (2011 - 2016)
- Director, Director of Infusion Services (ITA) (2015 - 2016)
- Panel member adult oncology committee, National comprehensive cancer network (2010 - 2016)
- Panel Member Multiple Myeloma Committee, National Comprehensive Cancer Network (2007 - 2011)
Publications
-
-
Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia
Medeiros, B. C. (2009). Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(3), 474–474. -
Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report.
Chan, S. M., George, T., Cherry, A. M., & Medeiros, B. C. (2009). Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report. Cases Journal, 2(1), 121-? -
Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia
Medeiros, B. C. (2009). Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(12), 2105–2105. -
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Medeiros, B. C. (2009). Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 360(17), 1787–1787. -
-
Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy
Pretz, J., & Medeiros, B. C. (2009). Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy. AMERICAN JOURNAL OF HEMATOLOGY, 84(10), 698–699. -
-
Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience
Medeiros, B. C., Othus, M., Fang, M., Roulston, D., & Appelbaum, F. R. (2010). Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. BLOOD, 116(13), 2224–2228. -
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge
Arredondo, A. R., Gotlib, J., Shier, L., Medeiros, B., Wong, K., Cherry, A., … George, T. I. (2010). Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. AMERICAN JOURNAL OF HEMATOLOGY, 85(8), 600–606. -
-
Plasma cell leukemia: concepts and management.
Liedtke, M., & Medeiros, B. C. (2010). Plasma cell leukemia: concepts and management. Expert Review of Hematology, 3(5), 543–49. -
Acute myeloid leukaemia in the elderly: a review
Pollyea, D. A., Kohrt, H. E., & Medeiros, B. C. (2011). Acute myeloid leukaemia in the elderly: a review. BRITISH JOURNAL OF HAEMATOLOGY, 152(5), 524–542. -
Unfavorable-risk cytogenetics in acute myeloid leukemia
Hong, W.-J., & Medeiros, B. C. (2011). Unfavorable-risk cytogenetics in acute myeloid leukemia. EXPERT REVIEW OF HEMATOLOGY, 4(2), 173–84. -
Cytarabine Dose for Acute Myeloid Leukemia
Medeiros, B. C., Othus, M., & Appelbaum, F. R. (2011). Cytarabine Dose for Acute Myeloid Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 364(22), 2167–2168. -
Microfluidic purification and analysis of hematopoietic stem cells from bone marrow
Schirhagl, R., Fuereder, I., Hall, E. W., Medeiros, B. C., & Zare, R. N. (2011). Microfluidic purification and analysis of hematopoietic stem cells from bone marrow. LAB ON A CHIP, 11(18), 3130–3135. -
-
Treatment advances have not improved the early death rate in acute promyelocytic leukemia
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., & Medeiros, B. C. (2012). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 133–36. -
Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., … Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30–37. -
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., … Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893–901. -
-
"It doesn't matter if you're black or white", does it?
Medeiros, B. C. (2012). "It doesn't matter if you're black or white", does it? LEUKEMIA RESEARCH, 36(2), 127–127. -
-
-
Unveiling the complexity of CK+ AML.
Medeiros, B. C. (2012). Unveiling the complexity of CK+ AML. Blood, 119(9), 1958–1959. -
Blood consult: monosomal karyotype acute myeloid leukemia
Garcia, J. S., Medeiros, B. C., & Appelbaum, F. R. (2012). Blood consult: monosomal karyotype acute myeloid leukemia. BLOOD, 119(24), 5659–5660. -
Aggressive EBV-associated Lymphoproliferative Disorder: A Prodrome to Diffuse Large B-cell Lymphoma?
Batra, R., Medeiros, B. C., Zehnder, J. L., Warnke, R. A., & Natkunam, Y. (2012). Aggressive EBV-associated Lymphoproliferative Disorder: A Prodrome to Diffuse Large B-cell Lymphoma? APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(3), 325–330. -
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels
Pollyea, D. A., Kohrt, H. E., Zhang, B., Zehnder, J., Schenkein, D., Fantin, V., … Medeiros, B. C. (2013). 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. LEUKEMIA & LYMPHOMA, 54(2), 408–10. -
Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., … Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957–960. -
CD19(-)CD45(low/-)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells
Kim, D., Park, C. Y., Medeiros, B. C., & Weissman, I. L. (2012). CD19(-)CD45(low/-)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells. LEUKEMIA, 26(12), 2530–2537. -
Novel agents in acute myeloid leukemia
Ungewickell, A., & Medeiros, B. C. (2012). Novel agents in acute myeloid leukemia. INTERNATIONAL JOURNAL OF HEMATOLOGY, 96(2), 178–185. -
CD11b expression and MK+ AML: A sign of impending doom?
Medeiros, B. C. (2013). CD11b expression and MK+ AML: A sign of impending doom? LEUKEMIA RESEARCH, 37(2), 121–121. -
Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options
Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., & Liedtke, M. (2012). Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options. HEMATOLOGY, 17(6), 325–328. -
-
A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.
Patel, S., Liedtke, M., Ngo, D., & Medeiros, B. C. (2013). A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Leukemia & Lymphoma, 54(10), 2231–2235. -
Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study
McGuire, A., Shier, L. R., Gotlib, J., Medeiros, B., Wong, K., Corless, C., … George, T. I. (2009). Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study. Presented at the 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, BOSTON,MA: NATURE PUBLISHING GROUP. -
Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21). -
A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma
Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., Medeiros, B. C., & Liedtke, M. (2012). A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma. BLOOD, 120(21). -
Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification
Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., Liedtke, M., … Zehnder, J. L. (2010). Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification. BLOOD, 116(21), 1357–58. -
A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347–47. -
Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., & Medeiros, B. C. (2009). Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. BLOOD, 114(22), 420–421. -
-
Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm
Becker, P. S., Medeiros, B. C., Appelbaum, F. R., Scott, B. L., Hendrie, P. C., Storer, B., … Estey, E. H. (2011). Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. BLOOD, 118(21), 1545–1545. -
Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm
Becker, P. S., Medeiros, B. C., Stein, A. S., Appelbaum, F. R., Scott, B. L., Delaney, C., … Estey, E. H. (2012). Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. BLOOD, 120(21). -
-
Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A., Rajwanshi, R., … Zehnder, J. (2009). Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(15). -
-
PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML)
Walter, B., Medeiros, B., Nielsen-Stoeck, M., Harrington, E., Powell, B., Schiffer, C., … Estey, E. (2010). PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML). Presented at the 15th Annual Meeting of the European-Hematology-Association, BARCELONA,SPAIN: FERRATA STORTI FOUNDATION. -
Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., … Alizadeh, A. A. (2009). Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). BLOOD, 114(22), 646–647. -
-
New treatment approaches for older adults with multiple myeloma
Wildes, T. M., Vij, R., Petersdorf, S. H., Medeiros, B. C., & Hurria, A. (2012). New treatment approaches for older adults with multiple myeloma. JOURNAL OF GERIATRIC ONCOLOGY, 3(3), 279–90. -
Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., … Shead, D. A. (2012). Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(10), 1211–19. -
Senior Adult Oncology
Hurria, A., Browner, I. S., Cohen, H. J., Denlinger, C. S., deShazo, M., Extermann, M., … Wildes, T. (2012). Senior Adult Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(2), 162–209. -
Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomes.
Jagsi, R., Chiang, A., Polite, B. N., Medeiros, B. C., McNiff, K., Abernethy, A. P., … Loehrer, P. J. (2013). Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomes. Journal of Oncology Practice / American Society of Clinical Oncology, 9(6), e290–7. -
Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia
Medeiros, B. C., Othus, M., Estey, E. H., Fang, M., & Appelbaum, F. R. (2014). Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 164(2), 245–250. -
-
Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic
Wildes, T. M., Stirewalt, D. L., Medeiros, B., & Hurria, A. (2014). Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(1), 128–136. -
Senior adult oncology, version 2.2014: clinical practice guidelines in oncology .
Hurria, A., Wildes, T., Blair, S. L., Browner, I. S., Cohen, H. J., deShazo, M., … Sundar, H. (2014). Senior adult oncology, version 2.2014: clinical practice guidelines in oncology . Journal of the National Comprehensive Cancer Network , 12(1), 82–126. -
-
Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia.
Medeiros, B. C. (2014). Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia. Acta Haematologica, 131(4), 200–201. -
Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia
Pierceall, W. E., Lena, R. J., Medeiros, B. C., Blake, N., Doykan, C., Elashoff, M., … Walter, R. B. (2014). Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. LEUKEMIA RESEARCH, 38(5), 564–568. -
NCCN clinical practice guidelines in oncology: multiple myeloma.
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Cohen, A. D., … Yunus, F. (2009). NCCN clinical practice guidelines in oncology: multiple myeloma. Journal of the National Comprehensive Cancer Network , 7(9), 908–942. -
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., … Shead, D. A. (2012). Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. Journal of the National Comprehensive Cancer Network , 10(10), 1211–1219. -
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.
Frankel, A. E., Woo, J. H., Ahn, C., Pemmaraju, N., Medeiros, B. C., Carraway, H. E., … Rowinsky, E. (2014). Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood, 124(3), 385–392. -
Monosomal karyotype acute myeloid leukemia: tread lightly.
Garcia, J. S., & Medeiros, B. C. (2015). Monosomal karyotype acute myeloid leukemia: tread lightly. Acta Haematologica, 133(4), 324–326. -
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia
Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA RESEARCH, 38(12), 1441–45. -
Polypharmacy in AML: the tip of the iceberg.
Patel, S., & Medeiros, B. C. (2014). Polypharmacy in AML: the tip of the iceberg. Leukemia Research, 38(11), 1378–1379. -
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Rakheja, D., Fuda, F., Vandergriff, T., Boriack, R., Medeiros, B. C., Frankel, A. E., & Chen, W. (2015). Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm. Human Pathology, 46(2), 322–326. -
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W.-J., … Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine, 21(2), 178–84. -
-
Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.
Medeiros, B. C., Othus, M., Fang, M., Appelbaum, F. R., & Erba, H. P. (2015). Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. Haematologica, 100(3), 331–335. -
G-CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm
Becker, P. S., Medeiros, B. C., Stein, A. S., Othus, M., Appelbaum, F. R., Forman, S. J., … Estey, E. H. (2015). G-CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. AMERICAN JOURNAL OF HEMATOLOGY, 90(4), 295–300. -
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
Swords, R. T., Erba, H. P., DeAngelo, D. J., Bixby, D. L., Altman, J. K., Maris, M., … Medeiros, B. C. (2015). Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. BRITISH JOURNAL OF HAEMATOLOGY, 169(4), 534–543. -
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W.-J., … Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. NATURE MEDICINE, 21(2), 90–96. -
Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose Interleukin-2 for treatment of metastatic renal cell carcinoma
Medeiros, B. C., Kogel, K. E., & Kane, M. A. (2003). Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose Interleukin-2 for treatment of metastatic renal cell carcinoma. TRANSFUSION AND APHERESIS SCIENCE, 29(1), 25–27. -
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States
Medeiros, B. C., Satram-Hoang, S., Hurst, D., Hoang, K. Q., Momin, F., & Reyes, C. (2015). Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. ANNALS OF HEMATOLOGY, 94(7), 1127–38. -
Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis
Percival, M.-E. M., Tao, L., Medeiros, B. C., & Clarke, C. A. (2015). Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis. CANCER, 121(12), 2004–2012. -
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.
Liedtke, M., Dunn, T., Dinner, S., Coutré, S. E., Berube, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leukemia Research, 38(12), 1441–1445. -
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
Khalife, J., Radomska, H. S., Santhanam, R., Huang, X., Neviani, P., Saultz, J., … Marcucci, G. (2015). Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia. -
Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.
Percival, M.-E. M., Medeiros, B. C., Tian, L., Robeson, S., Laport, G. G., Johnston, L. J., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation. -
-
Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California.
Abrahão, R., Ribeiro, R. C., Medeiros, B. C., Keogh, R. H., & Keegan, T. H. (2015). Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California. Cancer. -
Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy.
Behbehani, G. K., Samusik, N., Bjornson, Z. B., Fantl, W. J., Medeiros, B. C., & Nolan, G. P. (2015). Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy. Cancer Discovery, 5(9), 988–1003. -
Chemotherapy dose in obese AML patients: To cap or not to cap?
Percival, M.-E. M., & Medeiros, B. C. (2015). Chemotherapy dose in obese AML patients: To cap or not to cap? LEUKEMIA RESEARCH, 39(1), 30–32. -
Management considerations in older patients with AML: a 2014 perspective.
Medeiros, B. C. (2014). Management considerations in older patients with AML: a 2014 perspective. [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, 55(10), 1803–1807. -
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård, L. S., Medeiros, B. C., Sengeløv, H., Nørgaard, M., Andersen, M. K., Dufva, I. H., … Nørgaard, J. M. (2015). Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. -
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.
Pasquini, M. C., Zhang, M.-J., Medeiros, B. C., Armand, P., Hu, Z.-H., Nishihori, T., … Weisdorf, D. J. (2016). Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation , 22(2), 248–57. -
Chemotherapy options for previously untreated acute myeloid leukemia
Lynch, R. C., & Medeiros, B. C. (2015). Chemotherapy options for previously untreated acute myeloid leukemia. EXPERT OPINION ON PHARMACOTHERAPY, 16(14), 2149–2162. -
-
-
Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study.
Abrahão, R., Keogh, R. H., Lichtensztajn, D. Y., Marcos-Gragera, R., Medeiros, B. C., Coleman, M. P., … Keegan, T. H. (2016). Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study. British Journal of Haematology. -
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., … Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253–59. -
Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach.
Jonas, B. A., & Medeiros, B. C. (2016). Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach. Oncology (Williston Park, N.Y.), 30(4). -
-
Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (> 5 years)
Medeiros, B. C., Minden, M. D., Schuh, A. C., Schimmer, A. D., Yee, K., Lipton, J. H., … Brandwein, J. M. (2007). Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (> 5 years). LEUKEMIA & LYMPHOMA, 48(1), 65–71. -
Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation
Medeiros, B. C., Chun, K., Kamel-Reid, S., & Lipton, J. (2007). Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation. AMERICAN JOURNAL OF HEMATOLOGY, 82(8), 758–760. -
Absence of FTL3 mutations in patients with JAK2(V617F) mutation negative essential thrombocythemia
Medeiros, B. C., Zhang, T., Lipton, J. H., & Kamel-Reid, S. (2007). Absence of FTL3 mutations in patients with JAK2(V617F) mutation negative essential thrombocythemia. AMERICAN JOURNAL OF HEMATOLOGY, 82(4), 293–294. -
Management of invasive Aspergillosis in acute myelogenous leukemia.
Medeiros, B. C. (2016). Management of invasive Aspergillosis in acute myelogenous leukemia. Clinical Advances in Hematology & Oncology : H&O, 14(7), 502–4. -
-
Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros, B. C., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Chan, S. M., & SWORDS, R. (2016). Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. -
Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients.
Østgård, L. S., Nørgaard, M., Sengeløv, H., Medeiros, B. C., Kjeldsen, L., Overgaard, U. M., … Nørgaard, J. M. (2016). Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients. Oncotarget. -
Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.
Huang, M., Garcia, J. S., Thomas, D., Zhu, L., Nguyen, L. X. T., Chan, S. M., … Mitchell, B. S. (2016). Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget. -
Why do subjects on clinical trials discontinue therapy? Do we really know?
Medeiros, B. C., & Gale, R. P. (2016). Why do subjects on clinical trials discontinue therapy? Do we really know? Leukemia Research, 51, 19–21. -
NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016.
VanderWalde, N., Jagsi, R., Dotan, E., Baumgartner, J., Browner, I. S., Burhenn, P., … Hurria, A. (2016). NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. Journal of the National Comprehensive Cancer Network , 14(11), 1357–70. -
-
NCCN Guidelines (R) Insights Older Adult Oncology, Version 2.2016 Featured Updates to the NCCN Guidelines
VanderWalde, N., Jagsi, R., Dotan, E., Baumgartner, J., Browner, I. S., Burhenn, P., … Hurria, A. (2016). NCCN Guidelines (R) Insights Older Adult Oncology, Version 2.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(11), 1357–70. -
A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia.
Shahmarvand, N., Oak, J. S., Cascio, M. J., Alcasid, M., Goodman, E., Medeiros, B. C., … Ohgami, R. S. (2017). A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia. International Journal of Laboratory Hematology. -
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia
Carey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., … Agarwal, A. (2017). Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. CELL REPORTS, 18(13), 3204–3218. -
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
Swords, R. T., Watts, J., Erba, H. P., Altman, J. K., Maris, M., ANWER, F., … DeAngelo, D. J. (2017). Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer Journal, 7(2). -
-
Novel Therapeutics in Acute Myeloid Leukemia.
DiNardo, C. D., Stone, R. M., & Medeiros, B. C. (2017). Novel Therapeutics in Acute Myeloid Leukemia. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting, 37, 495–503. -
relapsed or refractory acute myeloid leukemia.
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., … Tallman, M. S. (2017). relapsed or refractory acute myeloid leukemia. Blood. -
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., … Döhner, H. (2017). Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. The New England Journal of Medicine. -
Unpaired extracellular cysteine mutations of CSF3R mediate gain or loss of function.
Zhang, H., Means, S., Schultz, A. R., Watanabe-Smith, K., Medeiros, B. C., Bottomly, D., … Tyner, J. W. (2017). Unpaired extracellular cysteine mutations of CSF3R mediate gain or loss of function. Cancer Research. -
Isocitrate dehydrogenase mutations in myeloid malignancies
Medeiros, B. C., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Chan, S. M., & SWORDS, R. (2017). Isocitrate dehydrogenase mutations in myeloid malignancies. LEUKEMIA, 31(2), 272–81. -
Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation.
Amitay-Laish, I., Sundram, U., Hoppe, R. T., Hodak, E., Medeiros, B. C., & Kim, Y. H. (2017). Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation. JAAD Case Reports, 3(4), 310–15. -
Long non-coding RNAs: another brick in the wall of normal karyotype acute myeloid leukemia?
Medeiros, B. C. (2017). Long non-coding RNAs: another brick in the wall of normal karyotype acute myeloid leukemia? Haematologica, 102(8), 1301–3. -
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Kurtz, S. E., Eide, C. A., Kaempf, A., Khanna, V., Savage, S. L., Rofelty, A., … Tyner, J. W. (2017). Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proceedings of the National Academy of Sciences of the United States of America. -
Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.
Sorror, M. L., Storer, B. E., Fathi, A. T., Gerds, A. T., Medeiros, B. C., Shami, P., … Estey, E. H. (2017). Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA Oncology. -
Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study.
Østgård, L. S., Nørgaard, M., Medeiros, B. C., Friis, L. S., Schoellkopf, C., Severinsen, M. T., … Nørgaard, J. M. (2017). Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017736728. -
Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: a National Population-Based Cohort Study.
Østgård, L. S., Lund, J. L., Nørgaard, J. M., Nørgaard, M., Medeiros, B. C., Nielsen, B., … Sengeløv, H. (2017). Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: a National Population-Based Cohort Study. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide or azacitidine in persons =65 years with newly-diagnosed acute myeloid leukemia.
Medeiros, B. C., McCaul, K., Kambhampati, S., Pollyea, D. A., Kumar, R., Silverman, L. R., … Gale, R. P. (2017). Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide or azacitidine in persons =65 years with newly-diagnosed acute myeloid leukemia. Haematologica. -
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo, D. J., George, T. I., Linder, A., Langford, C., Perkins, C., Ma, J., … Gotlib, J. (2017). Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. -
Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells
Xu, G. W., Toth, J. I., da Silva, S. R., Paiva, S.-L., Lukkarila, J. L., Hurren, R., … Schimmer, A. D. (2014). Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells. PLOS ONE, 9(4). -
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.
Walter, R. B., Othus, M., Orlowski, K. F., McDaniel, E. N., Scott, B. L., Becker, P. S., … Estey, E. H. (2017). Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica. -
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., … Appelbaum, F. R. (2018). Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Leukemia Research, 67, 17–20. -
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.
Medeiros, B. C., Possick, J., & Fradley, M. (2018). Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Reviews. -
Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study.
Østgård, L. S., Nørgaard, M., Pedersen, L., Østgård, R. D., Medeiros, B. C., Overgaard, U. M., … Jensen, M. K. (2018). Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study. British Journal of Haematology. -
-
A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.
Medeiros, B. C., Tanaka, T. N., Balaian, L., Bashey, A., Guzdar, A., Li, H., … Ball, E. D. (2018). A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia. -
-
AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies
Stein, E. M., Altman, J. K., Collins, R., DeAngelo, D. J., Fathi, A. T., Flinn, I., … de Botton, S. (2014). AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies. BLOOD. AMER SOC HEMATOLOGY. -
Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD. AMER SOC HEMATOLOGY. -
Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy
Pollyea, D. A., Zehnder, J. L., Coutre, S., Gotlib, J., Gallegos, L., Greenberg, P., … Medeiros, B. C. (2012). Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy. BLOOD. AMER SOC HEMATOLOGY. -
-
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Dinner, S., Dunn, T. J., Price, E., Coutré, S. E., Gotlib, J., Berube, C., … Liedtke, M. (2018). A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. International Journal of Hematology. -
Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality
Sorror, M. L., Storer, B. E., Elsawy, M., Fathi, A. T., Brunner, A., Gerds, A. T., … Estey, E. H. (2015). Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality. BLOOD. AMER SOC HEMATOLOGY. -
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., … Medeiros, B. C. (2018). CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017776112. -
-
-
-
-
-
-
-
-
-
-
-
-
Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models
Sorror, M. L., Storer, B. E., Elsawy, M., Fathi, A. T., Brunner, A. M., Gerds, A. T., … Estey, E. H. (2016). Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. BLOOD. AMER SOC HEMATOLOGY. -
-
-
-
-
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
Stein, E. M., DiNardo, C., Altman, J. K., Collins, R., DeAngelo, D. J., Kantarjian, H. M., … De Botton, S. (2015). Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. BLOOD. AMER SOC HEMATOLOGY. -
-
-
-
Preclinical Activity of a New Proteasome Inhibitor, MLN9708, in Acute Myelogenous Leukemias Expressing NPM1 Mutated Protein
Garcia, J. S., Huang, M., Medeiros, B. C., & Mitchell, B. S. (2014). Preclinical Activity of a New Proteasome Inhibitor, MLN9708, in Acute Myelogenous Leukemias Expressing NPM1 Mutated Protein. BLOOD. AMER SOC HEMATOLOGY. -
-
-
-
-
-
-
-
-
-
-
-
2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels
Pollyea, D. A., Kohrt, H. E., Zhang, B., Zehnder, J. L., Schenkein, D. P., Fantin, V., … Medeiros, B. C. (2011). 2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels. BLOOD. AMER SOC HEMATOLOGY. -
-
-
-
-
-
-
-
-
-
-
-
-
-
NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study
Ostgard, L. S. G., Norgaard, M., Pedersen, L., Ostgard, R., Friis, L. S., Schollkopf, C., … Jensen, M. K. (2018). NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study. CANCER MANAGEMENT AND RESEARCH, 10, 5043–51. -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.
Stein, E. M., Dinardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., … Tallman, M. S. (2017). Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.
Medeiros, B. C., Chan, S. M., Daver, N. G., Jonas, B. A., & Pollyea, D. A. (2019). Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. American Journal of Hematology. -
NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study.
Østgård, L. S., Nørgaard, M., Pedersen, L., Østgård, R., Friis, L. S., Schöllkopf, C., … Jensen, M. K. (2018). NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study. Cancer Management and Research, 10, 5043–5051. -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.
Narayan, R., Olsson, N., Wagar, L. E., Medeiros, B. C., Meyer, E., Czerwinski, D., … Levy, R. (2019). Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. PloS One, 14(7), e0219547. -
-
-
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.
DeAngelo, D. J., Walker, A. R., Schlenk, R. F., Sierra, J., Medeiros, B. C., Ocio, E. M., … Stuart, R. K. (2019). Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leukemia Research, 85, 106197. -
Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study.
Tøstesen, M., Nørgaard, M., Nørgaard, J. M., Medeiros, B. C., Marcher, C. W., Overgaard, U. M., … Østgård, L. S. (2019). Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study. Clinical Epidemiology, 11, 769–780. -
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
Garcia, J. S., Bhatt, S., Fell, G., Sperling, A. S., Burgess, M., Keshishian, H., … Letai, A. (2019). Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. American Journal of Hematology. -
Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia.
Döhner, K., Thiede, C., Jahn, N., Panina, E., Gambietz, A., Larson, R. A., … Bloomfield, C. D. (2019). Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. -
Functional characterization of two rare BCR-FGFR1+ leukemias.
Barnes, E. J., Leonard, J., Medeiros, B., Druker, B. J., & Tognon, C. E. (2020). Functional characterization of two rare BCR-FGFR1+ leukemias. Cold Spring Harbor Molecular Case Studies. -
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.
Pagel, J. M., Othus, M., Garcia-Manero, G., Fang, M., Radich, J. P., Rizzieri, D. A., … Appelbaum, F. R. (2020). Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. JCO Oncology Practice, JOP1900133. -
Single-cell mutational profiling enhances the clinical evaluation of AML MRD.
Ediriwickrema, A., Aleshin, A., Reiter, J. G., Corces, M. R., Köhnke, T., Stafford, M., … Majeti, R. (2020). Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Blood Advances, 4(5), 943–52. -
Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya, B. J., Chen, C.-C., Medeiros, B. C., McGuiness, C. B., Wilson, S. D., Walsh, E. H., & Wade, R. L. (2020). Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database. Journal of Managed Care & Specialty Pharmacy, 1–11. -
Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).
Lin, T. L., Medeiros, B. C., Uy, G. L., Newell, L. F., Ritchie, E. K., Stuart, R. K., … Cortes, J. E. (2018). Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML). JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Azizi, A., Ediriwickrema, A., Dutta, R., Patel, S. A., Shomali, W., Medeiros, B., … Zhang, T. (2020). Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leukemia & Lymphoma, 1–8. -
Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia.
Horvath Walsh, L. E., Rider, A., Piercy, J., Pike, J., Wilson, S., Pandya, B. J., & Medeiros, B. C. (2019). Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia. Oncology and Therapy, 7(1), 67–81. -
Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial
Lancet, J., Uy, G. L., Cortes, J., Newell, L. F., Lin, T. L., Ritchie, E., … Medeiros, B. C. (2017). Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(3), S31–S32. -
Epidemiology and impact of preceding or underlying disease in secondary acute myeloid leukemia
Ostgard, L. S. G., & Medeiros, B. C. (2018). Epidemiology and impact of preceding or underlying disease in secondary acute myeloid leukemia. HEMASPHERE, 2, 153–55. -
Multicenter 11-Year Experience of Outcomes After Intensive Versus Less-Intensive Therapy for Patients with Acute Myeloid Leukemia: Focus on Older and Medically Infirm Patients
Sorror, M., Storer, B., Fathi, A., Brunner, A., Gerds, A., Sekeres, M., … Estey, E. (2020). Multicenter 11-Year Experience of Outcomes After Intensive Versus Less-Intensive Therapy for Patients with Acute Myeloid Leukemia: Focus on Older and Medically Infirm Patients. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.
Voso, M. T., Larson, R. A., Jones, D., Marcucci, G., Prior, T., Krauter, J., … Lo-Coco, F. (2020). Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Advances, 4(19), 4945–54. -
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study
Sorror, M. L., Storer, B. E., Gerds, A. T., Medeiros, B. C., Shami, P. J., Galvin, J. P., … Estey, E. H. (2019). Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 25(3). -
Overall Survival (OS) by Outpatient versus Inpatient Consolidation in a Phase 3 Study of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)
Kolitz, J., Strickland, S., Cortes, J., Hogge, D., Lancet, J., Goldberg, S., … Medeiros, B. (2017). Overall Survival (OS) by Outpatient versus Inpatient Consolidation in a Phase 3 Study of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 17, S287. -
Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)
Medeiros, B., Hogge, D., Newell, L., Bixby, D., Solomon, S., Strickland, S., … Lancet, J. (2017). Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 17, S286. -
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Larson, R. A., Mandrekar, S. J., Huebner, L. J., Sanford, B. L., Laumann, K., Geyer, S., … Stone, R. M. (2021). Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. -
Plasma Microbial Cell-free DNA Next Generation Sequencing in the Diagnosis and Management of Febrile Neutropenia.
Benamu, E., Gajurel, K., Anderson, J. N., Lieb, T., Gomez, C. A., Seng, H., … Deresinski, S. (2021). Plasma Microbial Cell-free DNA Next Generation Sequencing in the Diagnosis and Management of Febrile Neutropenia. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. -
Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.
Sorror, M. L., Storer, B. E., Fathi, A. T., Brunner, A. M., Gerds, A. T., Sekeres, M. A., … Estey, E. H. (2021). Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. Blood. -
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Rucker, F. G., Du, L., Luck, T. J., Benner, A., Krzykalla, J., Gathmann, I., … Dohner, K. (2021). Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. -
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
Sorror, M. L., Storer, B. E., Fathi, A. T., Brunner, A., Gerds, A. T., Sekeres, M. A., … Estey, E. H. (2021). Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood, 138(5), 387–400. -
Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.
Raychaudhuri, S., Yurkiewicz, I., Mannis, G. N., Medeiros, B. C., Coutre, S. E., Muffly, L. S., & Liedtke, M. (2021). Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.
Gerds, A. T., Scott, B. L., Greenberg, P. L., Lin, T. L., Pollyea, D. A., Verma, A. K., … Donnellan, W. B. (1800). Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. Blood Advances. -
Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia.
Miranti, E., Ho, D. Y., Enriquez, K., Subramanian, A. K., Medeiros, B. C., & Epstein, D. J. (2022). Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma, 1–7. -
Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study.
Maeng, C. V., Christiansen, C. F., Liu, K. D., Kamper, P., Christensen, S., Medeiros, B. C., & Ostgard, L. S. (2022). Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study. Leukemia & Lymphoma, 1–11. -
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn, N., Jahn, E., Saadati, M., Bullinger, L., Larson, R. A., Ottone, T., … Döhner, K. (2022). Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia. -
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients.
Sorror, M. L., Gooley, T. A., Storer, B. E., Gerds, A. T., Sekeres, M. A., Medeiros, B. C., … Estey, E. (2022). An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients. Blood. -
Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms
Gauthier, J., Furtuna, B., Mangiavacchi, J., Gholami, S., Ferres, J. L., Dodhia, R., … Sorror, M. L. (2022). Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms. BLOOD. AMER SOC HEMATOLOGY. -
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
Garcia-Manero, G., Podoltsev, N. A., Othus, M., Pagel, J. M., Radich, J. P., Fang, M., … Erba, H. P. (2023). A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia.
Practice Locations
SHC- Hematology Palo Alto, CA
Palo Alto, CAPatient Reviews
(67 reviews)
Great doctor!!
I have been seeing Dr Medeiros for over 16 years now and I will never change doctors. He has always been attentive and caring.
Very thoughtful and detail oriented. Has good bedside manner.
We feel so very comfortable with Dr Medeiros. He knows our past journey and makes us feel like he is invested in our future.We are so blessed to have him in our corner.
Bruno is thorough and always a pleasure to see.
So happy to have Dr. Medeiros as my doctor for the past 15 3/4 years. He has always been very nice to me
Bruno Medeiros is very caring and always answers questions with knowledge of the subject.
He is so professional, friendly & compassionate. Highly recommend!
Fantastic doctor. Cares about my medical as well as mental well being.
He’s No slacker! Always on top of things. In charge personality.
Leaves me feeling he’s very confident of his skills, knowledge, and resources.
Good guy, wonderful Doctor.
Dr. Medeiros & Jamie are always so professional, helpful & friendly! Thank you to everyone!
Dr. Mederios is one of the best doctors to have on your care team. He knows his stuff and explains everything thoroughly. He listens and genuinely cares. I trust him completely.
Dr. Bruno Medeiros makes excellent jobs to cure my myeloma on pancreas with 9 cm and pelvis with 15 cm after cocktail VRD chemotherapy over 2 years and developing Velcade maintenance over 5 years in stringent remission without further treatments over 3 yrs from Feb. 2011. Now it is a miracle thing which I am cancer free 3 yrs, Millions Thanks to Dr. Bruno Medeiros.
Dr. Mederios is a fantastic doctor. He saved my life with his knowledge and his team. I am so grateful. Thanks again Dr. Mederios.
Brief. To the point, just his nature or personality
He is very reassuring and thorough. Been with him for 6 years and wouldn’t have recovered from AML without his care.
I'm thankful to have him as my Physician.
great doctor
Bruno is very easy to talk to and very knowledgeable . The video appointments work fine but I miss seeing him in person.
Thankful to have Dr. Bruno Carneiro as our doctor. He is confident, professional and thorough.
He's the best. Forever grateful for his care.
High level of confidence! Terrific!
Dr. Medeiros is great as usual. Direct a quality we like and at the same time caring we have total confidence in him and Stanford.
I very much appreciate the care provided by Dr. Medeiros. I'm happy for him in his new role, AND I'm delighted he'll on time to see some patients at Stanford.
I am very satisfied.
Good.
All very good - great doctor.
Dr. Medeiros is the perfect combination of professionalism, competence, friendliness and caring. I was so happy to learn he is also the doctor of a friend.
Far exceeded the care and concern of everyone we came across.
My care provider is excellent.
V. good.
Always excellent!
Excellent staff team members. Very helpful & knowledgeable.
This was my first visit, and I am amazed at the quality of staff & Dr. Medeiros.
Excellent visit with post-doctoral fellow and Dr. Medeiros.
Dr. Medeiros is a great doctor he is very informative.
Very good.
The doctors were extremely knowledgeable and excellent, clear communicators.
First visit; good show.
I have every confidence in Dr. Medeiros and feel that I am in excellent hands under his care & the care of his team.
Good experience.
Physician would not listen and seemed unwilling to care for my overall health as related to my cancer.
Have complete confidence in Dr. Medeiros to always explain options so we can make informed decisions for the treatment plan. Very bright and to us very caring.
Good-provider - I understood explanations.
I always feel very welcomed there.
Very pleased with treatment.
Dr. Modelros is a lovely knowledgeable person.
All my experiences have been very good. Have been seeing Dr. Bruno for two years. He is always on top of my condition and very supportive.
Initially I received very good information regarding my pathology.
Dr. Medeiros along with his entire hematology team and staff are the best I coudl ever ask for.
We are always happy to see Dr. Medeiros. He is direct and that is what we want but always has the right balance of levity and curiousness that makes my husband feel good about the visit.
This was an uncomfortable appointment because of poor communication about questions and issues of concern. It was the worst physician appointment I've ever had, so will not be returning to this doctor.
I am a patient of Dr. Coutre but had to see Dr. Carneiro since Dr. Coutrie was away. Dr. Carneiro is not professional and very RUDE.
I will recommend without doubts.
Not a single bad experience to note.
The staff was very helpful and friendly.
Very good experience.
Was seen by ? Resident prior to Dr. Medeiros who provided good information.
Dr. seemed to be having a bad day.
Dr. Medeiros was very personable and professional in his demeanor & care of patient. Made patient feel comfortable.
This was a follow-up 4 1/2 yrs. from start of treatment always good.
Vast improvement from past.
Everyone spent a good amount of time with us and were very attentive to our needs.
Dr. Medeiros (and his 'fellow') was very encouraging, and informative/thorough.
Extremely knowledgeable.
Eased my fears with genuine concern & answered my questions with confidence.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology orders
- View referral status
- Access medical records